Top 8 Russian Vaccine Manufacturers in 2014, including pipelines, partnership information, recent news and contact information, compiled by IMAPAC Pte Ltd, located in Singapore.
3. RECENT DEVELOPMENTS IN FORT GROUP
40m 120m
20m 100m
FORT GROUP’S NEW COMPLEX WILL HAVE THE CAPACITY TO PRODUCE UP TO
doses of
ABOUT
Formed on 25 Mar 2011
PHONE +7 812 45 66 300 FAX +7 812 45 66 301
ADDRESS
41B,
Grazhdansky Prospect,
St Petersburg, 195220
0
PRODUCT PIPELINE
s Ultrix s Seasonal & Pandemic Influenza Vaccines
seasonal
vaccine
influenza
other viral
vaccines
pandemic
influenza
vaccine
recombinant
proteins
doses of
doses of
doses of
NEWS Russia’s largest plant for the production of vaccines & one of the biggest in Eastern Europe was recently commissioned in the Yaltunovo area of the Ryazan region by Fort Group, a leading Russian investment group. The investment in the project amounted to 4.8 billion roubles ($150 million), the majority of which were provided by Vnesheconombank, one of Russia’s largest banks.
CONNECT WITH US ON
BACK TO MAP
Quick Fact This project is a collaboration between Fort Group & the Russian Academy of Medical Sciences.
4. ABOUT
PHONE/
FAX
+7 (495)
780 5076
8 Website
http://www.ntpha
rma.ru/en/
. Email
info@ntpharma.ru
ADDRESS
Business Center
"Linkor"
12, Aviakonstruktora
Mikoyana St.,
Moscow, Russia, 125252
COMPETITIVE ADVANTAGE
RECENT DEVELOPMENTS IN NT PHARMA
CONNECT WITH US ON
BACK TO MAP
1ST
Vaccine for
influenza with
intranasal form of
administration
Forms a stable
viral
resistance in
2 – 3
weeks
Manufactures
strains on cell
culture
eliminating side
allergic
reactions
Building a facility for production of vaccines and pharmaceuticals in the municipal area of
Pereslavl’-Zalessky, 150 kilometers (85 miles) northeast of Moscow
Aims at production of new generation vaccines, including a polyvalent human flu vaccine, &
pharmaceuticals for detoxification in oncological therapy & for treatment of amyotrophic lateral
sclerosis (ALS/Lou Gehrig’s disease)
Allows reduction by ½ the time required for culturing & production of the vaccine
Vital when dealing with vaccines for pandemic flu strains spreading
rapidly all over the world
Confirmed Speaker
Prof. Sayadyan Khachik
CEO, NT Pharma, Russia
DEVELOPING
VACCINE 0 w AdeVac-Flu
5. ABOUT
ABOUT
PHONE
617 923 1400
FAX
617 924 3454
8 Website
http://www.selecta
bio.com/
. Email
info@selectabio.com
ADDRESS
480 Arsenal St.,
Building One
Watertown, MA
02472 0
PRODUCT PIPELINE
s SEL-068 Universal human
papillomavirus (HPV)
vaccine
s Universal influenza vaccine
s Malaria vaccine
s Type 1 diabetes therapeutic
vaccine
CONNECT WITH US ON
BACK TO MAP
Rasnano Selecta
Biosciences
SELECTA BIOSCIENCES’ PARTNERS
Polaris
Venture
Partners
Selecta
Biosciences
OrbiMed
Advisors
Selecta
Biosciences
Selecta
Biosciences NanoDimension
Flagship
Ventures
Selecta
Biosciences
Invests in Selecta
Biosciences &
BIND Biosciences
to develop &
commercialize
vaccines & cancer
drugs through
expanded
operations in
Russia
VACCINES PRODUCED
SVP (Synthetic Vaccine Particles)
VACCINE DEVELOPING
Smoking Cessation, Malaria, Cancer
Selecta Biosciences, Inc. is a biopharmaceutical company that is developing a new class of targeted vaccines, synthetically engineered
& capable of inducing targeted antigen-specific immune responses to prevent & treat diseases. Selecta's proprietary Synthetic Vaccine Particle
(SVP™) platform is the bases for two product lines, targeted Synthetic Vaccine Particles (tSVP™) & targeted tolerogenic Synthetic Vaccine
Particles (t2SVP™).
The 1st activates immune responses & the 2nd induces antigen-specific immune
tolerance. Selecta is developing product candidate vaccines for smoking cessation,
type 1 diabetes, several infectious diseases (universal influenza, universal human
papillomavirus, & malaria), cancer, and allergies.
Confirmed Speaker
Natalia Bastrikova
Director, Business Development & Clinical Research, Selecta, Russia
6. ABOUT
ABOUT
PHONE +7 (495) 648 26 87
8 Website http://www.nanolek.ru/ . Email info@nanolek.ru
ADDRESS 127055, Moscow, Butyrsky Val st., 68/70, 1 Business Center "Baker Plaza", 4th Floor, Office 45
0
PRODUCT PIPELINE
wPrevenar 13
w(More than 5million doses are planned to be produced by the end 2014)
CONNECT WITH US ON
BACK TO MAP
DISTRIBUTION COUNTRIES
Russia
CIS
EU:
Grippol - Influenza Vaccine
Vaccines Produced
Ukraine
Slovakia
Kyrgyzstan
Azerbaijan
Belarus
Moldova
Georgia
Uzbekistan
Kazakhstan
NPO PETROVAX PHARM’S PARTNERS
Their pneumococcal vaccine is now manufactured at NPO Petrovax Pharm’s facilities.
Petrovax is among the first Russian companies working to set up full-cycle production locally.
Has recently completed a major project for the development, registration, manufacturing & promotion of a novel influenza vaccine
This partnership exemplifies the success of a Russian company teaming up with a global pharma leader in R&D & production.
2012
RUSSIAN MINISTRY OF HEALTH REGISTERED PETROVAX PHARM AS A LOCAL PRODUCER OF PREVENAR 13 (PCV 13) - VACCINE PRODUCED BY RUSSIA'S PETROVAX PHARM / PFIZER
7. ABOUT MICROGEN
Produces more than 400 immunobiological preparations such as
Vaccines | Immunobiological (Anatoxins) | Blood products | Bacteriophages |
Therapeutic & diagnostic serums | Patented medicines (>40 items)
ABOUT
Annual Sales
Volume
$2 - 500M PHONE
+7 4957 907 773
#2183
ADDRESS
Kozhevnicheskii pr.,4
Moscow, 113114
Russia
0
PRODUCT PIPELINE
w Diphtheria
w Tetanus & Poliomyelitis
(DTP) Vaccines
w DTP Hepatitis B
w Hib Infections
(DTP HepB Hib) Vaccines
CONNECT WITH US ON
BACK TO MAP
One of the
three largest
companies in
the Russian
medical
industry
A leader in the
development &
production of
immunobiological
preparations,
diagnostics, &
drugs
Producer of the
Influenza, BCG,
EnceVir, DTP,
Rubella, Hep B,
Rabies, Varicella,
Meningococcal,
Gonococcal
Vaccines
Under a new
national
immunobiological
programme
created between
Rostec (Russia) &
the MoH
Butantan
Institute
Microgen Technovation Microgen
Healthcare
RUSSIA'S MICROGEN & BRAZIL'S BUTANTAN INSTITUTE TO ENTER
INTO VACCINE DEVELOPMENT AGREEMENT
RUSSIA'S MICROGEN & INDIA'S TECHNOVATION HEALTHCARE HAD
PREVIOUSLY ENTERED INTO A SIMILAR VACCINE DEVELOPMENT
AGREEMENT Confirms Russia's interest to strengthen
its co-operation with Latin America in the
biopharmaceuticals sector
Enables technology exchange with the
Brazilian institution, one of the largest
dedicated to biomedical research in the
Latin American region
The Indian company will transfer
the technology for the production of
diphtheria, tetanus & poliomyelitis
(DTP) vaccines & DTP hepatitis B
& Hib infections (DTP HepB Hib)
vaccines to the Russian company
8. ABOUT NANOLEK
ABOUT
PHONE +7 (495) 648 26 87
8 Website http://www.nanolek.ru/ . Email info@nanolek.ru
ADDRESS 127055, Moscow, Butyrsky Val st., 68/70, 1 Business Center "Baker Plaza", 4th Floor, Office 45
0
PRODUCT PIPELINE
w VLP-based flu vaccine
CONNECT WITH US ON
BACK TO MAP
NANOLEK’S PARTNERS
DISTRIBUTION COUNTRIES
Belarus
Kazakhstan
Customs Union of Russia
(IPV) Inactivated Polio Vaccine
Influenza
Vaccines Produced
Nanolek (a joint venture between Rusnano with Russian Biotechnology company Epidbiomed) and privately-held us biotech firm Lentigen have signed a memorandum of understanding (MOU) on their intention to launch production of a novel VLP (virus-like particle)-based flu vaccine manufactured at Nanolek’s large-scale pharmaceutical production facility in Kirov, Russia.
Nanolek has signed an agreement with the Dutch biotech firm Bilthoven Biologicals (acquired last year by the Serum Institute of India; The Pharma Letter July 6, 2012) on establishing production of inactivated polio vaccine
Amount of investments range from $50 - $70 million
Under the terms of the agreement between the parties, Bilthoven Biologicals has provided the Russian companies with an exclusive license to manufacture and distribute the finished form of the vaccine in the territory of the Customs Union of Russia, Kazakhstan & Belarus
9. ABOUT
PHONE
+7 (495) 925 3074
FAX +7 (495) 626 9780
8 Website http://www.newvac.ru . Email info@newvac.ru
ADDRESS Str. Working, d. 2a, Block 1, of Khimki, Moscow Region, Russia
CONNECT WITH US ON
BACK TO MAP
Located in the town of Khimki just outside Moscow, NewVac is a biomed start-up established to focus on the development of innovative technology for cancer immunotherapy. According to Mr. Bugrov, the company’s mission is “the creation of a Russian-based innovative, world-class biomed platform for cancer treatment centered on patient-specific immunotherapy.”
NewVac is currently moving to clinical trials of its new low-molecular compounds that could be used as co-adjuvant & are expected to dramatically improve the company’s own therapeutic anti-tumoral vaccine technology.
Licensed to commercialize US cancer vaccine candidate in Russian market & do further Oncophage testing and carry out development programs using its own co- adjuvant technology
RECENT DEVELOPMENTS IN NEWVAC
DEVELOPING VACCINE
0
w Oncophage therapeutic Vaccine w Renal Cell Carcinoma Vaccine
NEWVAC IS A SUBSIDIARY OF
CHEMRAR HIGH TECH CENTER *
”
ONCOPHAGE IS AN ADVANCED THERAPEUTIC CANCER DRUG IN A FAMILY OF THE DEVELOPER’S PROPRIETARY PROPHAGE SERIES VACCINE CANDIDATES, “TESTED IN MORE THAN 850 PATIENTS IN MULTIPLE CANCERS IN MORE THAN 15 PHASE 1, 2 AND 3 CLINICAL TRIALS.”
- Agenus
AGENUS
NEWVAC
GRANTS NEWVAC EXCLUSIVE RIGHTS TO PRODUCE AND SELL ONCOPHAGE TO THE RUSSIAN & CIS MARKETS
10. ABOUT JSC BINNOPHARM
PHONE
+7 (495)
510-3288
8 Website
www.binnopharm.ru
. Email
info@binnopharm.ru
ADDRESS
3/1, 4-th Zapadny
proezd, Zelenograd,
Moscow, 124460,
0 Russia
PRODUCT PIPELINE
w Malaris
CONNECT WITH US ON
BACK TO MAP
Regevac B - Hep B
Cervical Cancer
Rotavirus vaccines
Pneumococcal vaccines
Vaccines Produced
ABOUT
in 2006
ZAO BINNOPHARM WAS FOUNDED
74% OF THE COMPANY’S
CHARTER CAPITAL
BELONGS TO
AFK SISTEMA
(Finance Corporation System)
RUR 4.3B AFK SISTEMA
HAS INVESTED IN A NEW
BIOTECHNOLOGICAL & PHARMACEUTICAL
COMPLEX OF BINNOPHARM CJSC
GlaxoSmithKline JSC Binnopharm
GLAXOSMITHKLINE & JSC BINNOPHARM HAVE FORMED A DEAL WITH
THE LATTER PRODUCING GSK’S CERVICAL CANCER, ROTAVIRUS, &
PNEUMOCOCCAL VACCINES IN RUSSIA
JSC BINNOPHARM is responsible for getting government
approval for the vaccines--the human papilloma
virus/cervical cancer shot Cervarix; the rotavirus vaccine
Rotarix; & the pneumococcal vaccine Synflorix & for
amping up its manufacturing facilities for the purpose
GlaxoSmithKline + Pfizer = ViiV (Est. 2009)
UCB JSC Binnopharm
32,000 SQM FACILITY
IN ZELENOGRAD
THE UNIT IS THE LARGEST GMP
STANDARD BIOPHARMACEUTICAL
PLANT IN RUSSIA
JSC ViiV
Binnopharm
ViiV supply bulk drug
materials to Binnopharm for
packaging, focusing initially
on its Combivir (lamivudine &
zidovudine), Kivexa (abacavir
sulfate & lamivudine) & Epivir
(lamivudine) brands.
70% of HIV+
patients
Would be treated
with domestically-produced
medicines
11. CONNECT WITH US ON
All information that you have just read was derived from secondary research - mainly from company & partner websites. This list is not in order of ranking nor comprehensive. For more information, visit us at our website.
Disclaimer
8
12. CONNECT WITH US ON
EARLY
BIRD
ENDS ON
1 SEPT
2014!
CLICK TO
FIND OUT
MORE!
